智通财经APP获悉，有着美股市场"大蓝筹"称号的医疗科技兼医药保健巨头强生(JNJ.US)于周三美股盘 前公布2025年第四季度核心业绩数据以及2026年业绩展望。按调整后口径，这家医疗保健领军者在第四 季度实现整体季度盈利约60亿美元——意味着实现同比增长22%，即每股2.46美元，分析师们此前普遍 预计每股利润约为2.44美元。第四季度营收245.6亿美元也高于华尔街分析师们普遍预期的241.6亿美 元，意味着实现同比超预期增长9.1%。 强生Q4整体销售额以及利润均高于华尔街预期，受益于血癌疗法Darzalex的强劲销售、银屑病药物 Tremfya的稳健增长，以及其医疗器械业务的强大韧性。 其规模最大的创新药(Innovative Medicine)部门本季度销售额增长10%，至157.6亿美元，高于预期的 153.7亿美元。 该公司预计2026年按业务经营统计口径(operational)计算的销售额指引区间约为995亿美元至1005亿美 元，根据伦敦LSEG汇编的分析师预期数据，高于华尔街分析师们普遍预估的约989亿美元。 强生管理层预计2026年全年的调整之后每股收益区间为11.43美元至11.6 ...

Core Viewpoint - Johnson & Johnson (JNJ.US) has reached an agreement with the Trump administration to lower drug prices in exchange for tariff exemptions, following similar agreements by other pharmaceutical companies [1] Group 1: Company Agreements - Johnson & Johnson is the latest pharmaceutical company to agree to lower drug prices, joining GlaxoSmithKline (GSK.US), Merck (MRK.US), and Novartis (NVS.US) [1] - Pfizer (PFE.US) and AstraZeneca (AZN.US) were among the first to agree to reduce prescription drug prices for tariff relief [1] - Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) also reached agreements to significantly lower prices for commonly used GLP-1 weight loss drugs for Medicare, Medicaid, and out-of-pocket patients [1]

Core Insights - U.S. pharmaceutical companies plan to increase the prices of at least 350 brand-name drugs in 2026, despite pressure from the Trump administration to lower prices [1] - The scale of price increases has expanded from over 250 drugs in the previous year, with a median increase of approximately 4%, consistent with 2025 [1] - Major drugs affected include vaccines for COVID-19, respiratory syncytial virus, shingles, and the cancer drug Ibrance [1] Group 1: Price Increases - Pfizer leads with the highest number of price increases, planning to raise prices on about 80 different drugs, including Ibrance, Nurtec, and Paxlovid [2] - Most of Pfizer's price increases are below 10%, but the COVID-19 vaccine Comirnaty will see a 15% increase, while some hospital medications will increase by over four times [2] - GlaxoSmithKline plans to raise prices on approximately 20 drugs and vaccines by 2% to 8.9%, emphasizing that price increases are necessary to support scientific innovation [2] Group 2: Price Decreases - A small number of drugs will see price reductions, including Boehringer Ingelheim's diabetes drug Jardiance, which will decrease by over 40% [3] - Jardiance is one of the ten drugs targeted for price negotiations under the U.S. government's Medicare plan for individuals aged 65 and older, with a two-thirds price cut agreed upon by Boehringer Ingelheim and Eli Lilly [3] Group 3: Government Agreements and Trends - Despite agreements with 14 pharmaceutical companies regarding some drug prices under government programs, the trend of price increases continues [4] - Companies like Pfizer, Sanofi, Boehringer Ingelheim, Novartis, and GlaxoSmithKline still plan to raise prices on certain drugs, indicating a strategy to maximize list prices while negotiating discounts behind the scenes [4] - Historical data shows that January is typically the month with the highest number of price adjustments, suggesting more increases and decreases are expected in early January [3][4]

Core Viewpoint - The agreement between President Trump and nine major pharmaceutical companies aims to significantly reduce drug prices for government Medicaid programs and cash-paying patients [1] Group 1: Agreement Details - The pharmaceutical companies involved include Bristol-Myers Squibb, Gilead Sciences, Merck, and Genentech, a subsidiary of Roche [1] - Other companies that have joined the agreement are Novartis, Amgen, Boehringer Ingelheim, Sanofi, and GlaxoSmithKline [1] - The agreement stipulates that pharmaceutical companies will lower prices for most drugs sold to low-income individuals under Medicaid and commit to achieving "substantial savings" on widely used medications [1]

Core Viewpoint - Swiss pharmaceutical giants Novartis (NVS.US) and Roche have expressed support for efforts to lower drug prices in the U.S. and are collaborating with the Trump administration towards this goal [1] Group 1: Company Actions - Novartis is in discussions with the Trump administration to find solutions for reducing drug costs for American citizens and addressing the price disparity between the U.S. and other high-income countries [1] - Roche has stated its support for the goal of lowering drug costs and encourages other countries to reward biopharmaceutical innovation [1] Group 2: Industry Context - The Trump administration has reached out to 17 pharmaceutical companies, urging them to significantly lower drug prices, with Pfizer (PFE.US) and AstraZeneca (AZN.US) being the first to agree to price reductions in exchange for tariff relief [1] - Recent agreements have been made by Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) to substantially reduce the prices of commonly used GLP-1 weight loss drugs for Medicare, Medicaid, and out-of-pocket patients [1]

Core Viewpoint - Novartis is preparing to propose a price reduction plan to President Trump by the end of this month, aiming to address the price disparity of drugs between the U.S. and other industrialized countries [1] Group 1: Financial Outlook - Novartis maintains its revenue growth forecast of 5% from 2024 to 2029, with profit growth expected to outpace revenue growth [1] Group 2: Strategic Preparations - The company has adequately prepared for the 15% tariff imposed by the U.S. on drugs imported from the EU, having significantly increased its inventory in the U.S. to sustain operations until mid-2026 [1]

Core Insights - Novo Nordisk has reduced the cash price of its diabetes treatment Ozempic to less than half of its monthly list price in response to political pressure for lower drug prices in the U.S. [1] Pricing and Accessibility - Patients can now pay $499 in cash per month for Ozempic, available in three dose sizes, through various platforms including the drug's official website and Novo Nordisk's patient assistance program [2] - GoodRx will also offer Ozempic and its weight loss counterpart Wegovy at the same price of $499 per month, accessible at over 70,000 pharmacies nationwide, enhancing affordability for patients [3] - This cash-pay offering aims to increase access for eligible Type 2 diabetes patients who lack insurance coverage for the weekly injection [3]

Core Viewpoint - The U.S. pharmaceutical stocks are experiencing declines following President Trump's letter urging major drug companies to reduce their prices to match those in other countries [1] Group 1: Stock Performance - GlaxoSmithKline is down 0.4% [1] - Eli Lilly and Novartis are both down 0.5% [1] - Pfizer has decreased by 0.7% [1] - AstraZeneca is down 1.6% [1] - Sanofi has dropped 1.7% [1] - Novo Nordisk is down 2.3% [1] Group 2: Government Action - President Trump sent letters to 17 major pharmaceutical companies, including Eli Lilly, Novo Nordisk, and Pfizer [1] - The letters urge these companies to immediately lower the prices they charge for drugs under the Medicaid program [1] - Trump demands that future drug prices be aligned with those in other countries [1]

Core Insights - Bristol Myers Squibb and Pfizer will sell their blood thinner Eliquis directly to patients at a discount of over 40% due to pressure from the Trump administration to lower drug prices [1][2] - The new pricing strategy aims to reduce the monthly cost from approximately $606 to $346, effective September 8, targeting uninsured, underinsured, and self-pay patients [2] - The discounted price remains significantly higher than the average out-of-pocket cost for commercially insured patients and the negotiated Medicare price set to take effect next year [3][4] Pricing Strategy - The new program bypasses traditional intermediaries like pharmacy benefit managers and insurers, allowing for direct sales to patients [2] - The initiative is designed to expand access to Eliquis, reduce out-of-pocket costs, and provide transparent pricing for patients [4][5] Market Context - The move is seen as a response to the Trump administration's executive order aimed at linking U.S. drug prices to those in other developed countries [6] - Analysts do not expect this program to negatively impact the net pricing for Bristol Myers Squibb and Pfizer, as they already provide substantial rebates to pharmacy benefit managers [6]

Core Viewpoint - The U.S. President Trump stated that drug prices in the U.S. are the highest globally and aims to reduce drug costs by 85% to 90%, which will subsequently lower healthcare insurance costs [1] Group 1 - The announcement highlights the significant disparity in drug pricing in the U.S. compared to other countries [1] - The proposed reduction in drug prices is expected to have a substantial impact on healthcare insurance expenses for consumers [1]